MENLO PARK, Calif.–(BUSINESS WIRE)–Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced that Pete…
Author: Business Wire
Ophthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors
NEW YORK–(BUSINESS WIRE)–Ophthotech announced the election of Calvin (Cal) W. Roberts, M.D., to Its Board of Directors, effective as of January 1.
Ocular Therapeutix™ Announces Completion of Debt Refinancing
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt…
Global Phacoemulsification Devices Market 2019-2023 | Glaucoma Surgery Combined with Cataract Surgery Via Phacoemulsification to Boost Demand | Technavio
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/HealthCareEquipment?src=hash" target="_blank"gt;#HealthCareEquipmentlt;/agt;–The global phacoemulsification devices market is expected to post a CAGR of close to 4% du…
Eye Health America Celebrates Record-Breaking First Year
ATLANTA–(BUSINESS WIRE)–Eye Health America (EHA), a leader in eye care practice management, announced today its 2018 end-of-year recap, which included seven acquisitions of ophthalmology and optometry practices and ambulatory surgery centers across t…
2019 New Year’s Resolution: Give Your Eyes a Rest
CHATTANOOGA, Tenn.–(BUSINESS WIRE)–Employee benefits company Unum found nearly 40% of U.S. adults spend 12+ hours a day on devices, triggering symptoms of digital eye strain.
Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announces that the NDA for KPI-121 0.25% has been accepted for review by the U.S. FDA.
The Global Market for Ophthalmic Lasers (2018-2023) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Laser Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The Ophthalmic Laser market is projected to grow at a CAGR of 6.09% to reach US$706.588 million by 2023, from US$495.529 million in 2017. Growing prevalence of ophthalmic diseases like glaucoma, cataract and other vision related issues and increasing initiatives by the government to control visual impairment are expected to drive the growth of the mark
TPG Capital backs BVI to Acquire PhysIOL Group SA
WALTHAM, Mass.–(BUSINESS WIRE)–BVI (Beaver-Visitec International), a leading developer, manufacturer, and marketer of specialized surgical devices and custom procedure packs for the ophthalmic marketplace, announced today it has signed a definitive a…
Ocular Therapeutix™ Added to Nasdaq Biotechnology Index
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt…
Resumen: Satralizumab de Chugai obtiene la designación de terapia innovadora de la FDA para la neuromielitis óptica y enfermedades del espectro de la neuromielitis óptica
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado que la Administración de Alimentos y Fármacos de EE. UU. (FDA en sus siglas en inglés) ha concedido la designación de terapia revolucionaria al antic…
Samenvatting: Chugai’s Satralizumab ontvangt FDA doorbraaktherapie-aanduiding voor Neuromyelitis Optica en Neuromyelitis Optica Spectrumstoornissen
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde aan dat de Amerikaanse Food and Drug Administration (FDA) doorbraaktherapie-aanduiding voor Chugai’s anti-interleukine-6 (IL-6) receptor gehumaniseerde recycling antil…
FDA簽發中外製藥的satralizumab為視神經脊髓炎及泛視神經脊髓炎的突破性治療藥物認證
東京–(BUSINESS WIRE)–(美國商業資訊) — 中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)宣布，美國食Ø…
La FDA accorde au satralizumab de Chugai la désignation de thérapie novatrice pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence américaine des produits alimentaires et médicamenteux (Food and Drug Administration, FDA) a octroyé la désignation de thérapie novatrice à l’anticorps de recyclage humanisé anti-récepteur de l’interleukine-6 (IL-6) de Chugai, le satralizumab, un médicament expérimental pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique (NMO/NMOSD). « Le satralizumab est
Ophthalmic Ultrasound Systems Markets with Forecasts from 2018 to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Ultrasound Systems Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic ultrasound systems market is expected to reach US$3.167 billion by 2023 from US$2.008 billion in 2017 growing at a CAGR of 7.89%. The market is expected to show a significant growth during the given forecast period. The growth may be attributed to the increasing prevalence of the eye diseases needing ophthalmic ultras
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Global Ocular Inflammation Treatment Market (2019-2023) is Expected to Grow at a CAGR of More Than 6% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ocular Inflammation Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The ocular inflammation treatment market will register a CAGR of more than 6% by 2023. The technological advances in drug delivery to push growth in the market. The increasing need for novel drug delivery systems has led to the advent of intravitreal implants, which are small hair-stranded sized devices that are implanted into the middle layer of the e
Satralizumab von Chugai erhält von FDA den Status „Breakthrough Therapy“ für Neuromyelitis optica und Neuromyelitis-optica-Spektrum-Erkrankungen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab bekannt, dass die US-amerikanische Zulassungsbehörde FDA den Status „Breakthrough Therapy“ (Durchbruchtherapie) für Chugais humanisierten, rezyklierenden An…
Physicians’ Education Resource® Presents the 16th Annual Winter Lung Cancer Conference™
CRANBURY, N.J.–(BUSINESS WIRE)–Physicians’ Education Resource® Presents the 16th Annual Winter Lung Cancer Conference™
Riassunto: Satralizumab di Chugai ha ottenuto dalla FDA la designazione di terapia innovativa per la neuromielite ottica e i disturbi dello spettro della neuromielite ottica
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha annunciato in data odierna che l’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) ha concesso la designazione di terap…